{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:03:19Z","timestamp":1768435399741,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Glucocorticoid-induced osteoporosis (GIO) is a secondary cause of bone loss. Bisphosphonates approved for GIO, might induce jaw osteonecrosis; thus additional therapeutics are required. Adenosine receptor agonists are positive regulators of bone remodeling, thus the efficacy of adenosine receptor stimulation for treating GIO was tested. In a preventive study GIO was induced in Sprague-Dawley rats by methylprednisolone (MP) for 60 days. Animals were randomly assigned to receive polydeoxyribonucleotide (PDRN), an adenosine A2 receptor agonist, or PDRN and DMPX (3,7-dimethyl-1-propargylxanthine, an A<jats:sub>2<\/jats:sub> antagonist), or vehicle (0.9% NaCl). Another set of animals was used for a treatment study, following the 60 days of MP-induction rats were randomized to receive (for additional 60 days) PDRN, or PDRN and DMPX (an adenosine A2 receptor antagonist), or zoledronate (as control for gold standard treatment), or vehicle. Control animals were administered with vehicle for either 60 or 120 days. Femurs were analyzed after treatments for histology, imaging, and breaking strength analysis. MP treatment induced severe bone loss, the concomitant use of PDRN prevented the developing of osteoporosis. In rats treated for 120 days, PDRN restored bone architecture and bone strength; increased b-ALP, osteocalcin, osteoprotegerin and stimulated the Wnt canonical and non-canonical pathway. Zoledronate reduced bone resorption and ameliorated the histological features, without significant effects on bone formation. Our results suggest that adenosine receptor stimulation might be useful for preventing and treating GIO.<\/jats:p>","DOI":"10.3389\/fphar.2017.00558","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T07:04:38Z","timestamp":1504595078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model"],"prefix":"10.3389","volume":"8","author":[{"given":"Gabriele","family":"Pizzino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Irrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Galfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Oteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Atteritano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Mannino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Aliqu\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe P.","family":"Anastasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Cutroneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Altavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1476-5381.2008.00100.x","article-title":"Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.","volume":"156","author":"Bitto","year":"","journal-title":"Br. J. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/jcpe.12010","article-title":"Adenosine receptor stimulation by polynucleotides (PDRN) reduces inflammation in experimental periodontitis.","volume":"40","author":"Bitto","year":"2013","journal-title":"J. Clin. Periodontol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1677\/JOE-08-0552","article-title":"Protective effect of genistein aglycone on the development of osteonecrosis of the femoral head and secondary osteoporosis induced by methylprednisolone in rats.","volume":"201","author":"Bitto","year":"","journal-title":"J. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1002\/art.30538","article-title":"Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A(2A) receptor.","volume":"63","author":"Bitto","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1210\/me.2003-0498","article-title":"The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice.","volume":"18","author":"Bodine","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1517\/14656566.2013.761975","article-title":"Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.","volume":"14","author":"Bultink","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1089\/scd.2012.0432","article-title":"Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages.","volume":"22","author":"Ciciarello","year":"2013","journal-title":"Stem Cells Dev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bone.2013.08.016","article-title":"Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.","volume":"57","author":"Gifre","year":"2013","journal-title":"Bone"},{"key":"B9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11914-014-0197-0","article-title":"The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.","volume":"12","author":"Gua\u00f1abens","year":"2014","journal-title":"Curr. Osteoporos. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/S0024-3205(03)00547-2","article-title":"Polydeoxyribonucleotide (PDRN) promotes human osteoblast proliferation: a new proposal for bone tissue repair.","volume":"73","author":"Guizzardi","year":"2003","journal-title":"Life Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.micron.2007.05.003","article-title":"Effects of heat deproteinate bone and polynucleotides on bone regeneration: an experimental study on rat.","volume":"38","author":"Guizzardi","year":"2007","journal-title":"Micron"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1096\/fj.13-231233","article-title":"Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.","volume":"27","author":"He","year":"2013","journal-title":"FASEB J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00223-002-2015-4","article-title":"Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.","volume":"72","author":"Hornby","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/art.27219","article-title":"Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice.","volume":"62","author":"Kara","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nature10763","article-title":"The contribution of bone to whole-organism physiology.","volume":"481","author":"Karsenty","year":"2012","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines.","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling.","volume":"116","author":"Krishnan","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.2653","article-title":"Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis.","volume":"18","author":"Maeda","year":"2012","journal-title":"Nat. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/bph.12227","article-title":"Activation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1\/2-mediated suppression of NF\u03baB nuclear translocation.","volume":"169","author":"Mediero","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1096\/fj.14-265066","article-title":"Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2.","volume":"29","author":"Mediero","year":"2015","journal-title":"FASEB J."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/srep04493","article-title":"Noncanonical Wnt5a enhances Wnt\/\u03b2-catenin signaling during osteoblastogenesis.","volume":"27","author":"Okamoto","year":"2014","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11357-008-9069-9","article-title":"Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation.","volume":"30","author":"Rauner","year":"2008","journal-title":"Age"},{"key":"B25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","article-title":"Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis.","volume":"93","author":"Rossini","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1563\/1548-1336-37.5.505","article-title":"Combined use of glucocorticoids and bisphosphonates may increase severity of bisphosphonate-related osteonecrosis of the jaw.","volume":"37","author":"Rutkowski","year":"2011","journal-title":"J. Oral Implantol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2559.2008.03127.x","article-title":"Stromal cells promote bone invasion by suppressing bone formation in ameloblastoma.","volume":"53","author":"Sathi","year":"2008","journal-title":"Histopathology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/(SICI)1099-0844(199906)17:2<107::AID-CBF815>3.0.CO;2-#","article-title":"Effect of polydeoxyribonucleotides on human fibroblasts in primary culture.","volume":"17","author":"Sini","year":"1999","journal-title":"Cell Biochem. Funct."},{"key":"B29","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1210\/jc.2013-3569","article-title":"The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial.","volume":"99","author":"Squadrito","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/jbmr.118","article-title":"Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells.","volume":"25","author":"Stevens","year":"2010","journal-title":"J. Bone. Miner. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S0024-3205(99)00104-6","article-title":"Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2 purinergic receptor subtypes.","volume":"64","author":"Thellung","year":"1999","journal-title":"Life Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures.","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.","volume":"13","author":"Van Staa","year":"2002","journal-title":"Osteoporos. Int."}],"updated-by":[{"DOI":"10.3389\/fphar.2022.1073618","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2017.00558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:19:38Z","timestamp":1667405978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2017.00558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":33,"alternative-id":["10.3389\/fphar.2017.00558"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00558","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fphar.2022.1073618","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]},"article-number":"558"}}